(Q27853209)

13 November 2016

title

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia (English)

1 reference

PubMed

PubMed publication ID

13 November 2016

1 reference

12

Eunhee Kim

0 references

Francesco Zaja

Francesco Zaja

7

0 references

Mario E Lacouture

Mario E Lacouture

24

0 references

Brunangelo Falini

Brunangelo Falini

40

0 references

Robin Foà

36

Robin Foà

0 references

Martin S. Tallman

41

Martin S Tallman

0 references

Pier Luigi Zinzani

38

Pier L Zinzani

0 references

Stefano A Pileri

34

Stefano A Pileri

0 references

Alessandro Rambaldi

28

Alessandro Rambaldi

0 references

author name string

Enrico Tiacci

1

0 references

Jae H Park

2

0 references

Luca De Carolis

3

0 references

Stephen S Chung

4

0 references

Alessandro Broccoli

5

0 references

Sasinya Scott

6

0 references

Sean Devlin

8

0 references

Alessandro Pulsoni

9

0 references

Young R Chung

10

0 references

Michele Cimminiello

11

0 references

Davide Rossi

13

0 references

Richard M Stone

14

0 references

Giovanna Motta

15

0 references

Alan Saven

16

0 references

Marzia Varettoni

17

0 references

Jessica K Altman

18

0 references

Antonella Anastasia

19

0 references

Michael R Grever

20

0 references

Achille Ambrosetti

21

0 references

Kanti R Rai

22

0 references

Vincenzo Fraticelli

23

0 references

Angelo M Carella

25

0 references

Ross L Levine

26

0 references

Pietro Leoni

27

0 references

Franca Falzetti

29

0 references

Stefano Ascani

30

0 references

Monia Capponi

31

0 references

Maria P Martelli

32

0 references

Christopher Y Park

33

0 references

Neal Rosen

35

0 references

Michael F Berger

37

0 references

Omar Abdel-Wahab

The New England Journal of Medicine

39

0 references

language of work or name

English

0 references

publication date

29 October 2015

0 references

published in

0 references

volume

373

0 references

issue

18

0 references

page(s)

1733-47

0 references

cites work

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

BRAF mutations in hairy-cell leukemia

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Mutations of the BRAF gene in human cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Mutational landscape and significance across 12 major cancer types

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Vemurafenib: the first drug approved for BRAF-mutant cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1)

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Distinct sets of genetic alterations in melanoma

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Mechanism and consequences of RAF kinase activation by small-molecule inhibitors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Hairy cell leukemia: short review, today's recommendations and outlook

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Phospho-ERK(THR202/Tyr214) is overexpressed in hairy cell leukemia and is a useful diagnostic marker in bone marrow trephine sections

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Soluble IL-2Rα (sCD25) exacerbates autoimmunity and enhances the development of Th17 responses in mice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

How I treat hairy cell leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Evolving concepts in the pathogenesis of hairy-cell leukaemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Eradication of minimal residual disease in hairy cell leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Optimal two-stage designs for phase II clinical trials

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

A microRNA signature specific for hairy cell leukemia and associated with modulation of the MAPK-JNK pathways.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

BRAF inhibition in refractory hairy-cell leukemia.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Regulation of hairy-cell survival through constitutive activation of mitogen-activated protein kinase pathways

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4811324

Correlation of serum levels of interleukin-1 family members with disease activity and response to treatment in hairy cell leukemia.

27 November 2018

1 reference